Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.53 |
| ▸ | PGR | P06401 | 9/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.43 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.39 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29782615 | 1.00 | BTK (0.53) | BTKPGRCYP2D6CYP2C9TRPC3 | |
| SCHEMBL28905210 | 1.00 | BTK (0.53) | BTKPGRCYP2D6CYP2C9TRPC3 | |
| SCHEMBL28499416 | 0.85 | BTK (0.60) | BTK | |
| SCHEMBL17699891 | 0.85 | BTK (0.60) | BTK | |
| SCHEMBL28501559 | 0.83 | BTK (0.49) | BTKPGRCYP2D6CYP2C9SMN1; SMN2 | |
| SCHEMBL29782450 | 0.83 | BTK (0.49) | BTKPGRCYP2D6CYP2C9SMN1; SMN2 | |
| SCHEMBL17707882 | 0.83 | BTK (0.49) | BTKPGRCYP2D6CYP2C9SMN1; SMN2 | |
| SCHEMBL20863093 | 0.74 | BTK (0.54) | BTK | |
| SCHEMBL29782655 | 0.74 | BTK (0.54) | BTK | |
| SCHEMBL13756990 | 0.72 | SMN1; SMN2 (0.54) | CYP2D6CYP2C9TRPC3TRPC7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| CN-107108583-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-10604504-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| US-10329274-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190119245-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-9920031-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9802915-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688629-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-10329274-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20170066740-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20170260160-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20190119245-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20160115126-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
| US-10604504-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | BTK 1/4885PGR 2849/4885CYP2D6 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.